The Weekly Five | 26 October – 1 November

Five studies worth your time this week, spanning lung SBRT, prostate fractionation, feeding-tube strategies, plasmacytoma treatment and metastasis-directed therapy.

1. KEYNOTE-867: pembrolizumab adds toxicity without improving outcomes after lung SBRT

In 448 patients with unresected early-stage NSCLC, adding pembrolizumab to SBRT did not improve event-free survival (HR 0.92). Grade 3–5 treatment-related toxicity increased from 3.7% to 20.4%, with five treatment-related deaths in the pembrolizumab group.

Read post

2. ASTRO 2026 recommends moderate hypofractionation across all prostate cancer risk groups

Updated ASTRO guidance recommends moderate hypofractionation for all localized prostate cancer risk groups, supports five-fraction SBRT in low- and intermediate-risk disease, and restricts ultrahypofractionated elective pelvic nodal irradiation to clinical trials.

Read post

3. SwallPEG finds no significant swallowing difference between gastrostomy strategies

In a randomized phase III trial, prophylactic PEG did not significantly improve six-month swallowing quality of life versus reactive placement (MDADI 69.5 vs 74.7). Early closure after 57 eligible patients limits conclusions about equivalence.

Read post

4. Lenalidomide–dexamethasone plus RT linked to longer disease control in solitary plasmacytoma

Ten-year progression-free survival was 71.8% with RT plus lenalidomide–dexamethasone versus 26.7% with RT alone. The 75-patient comparison was nonrandomized, and multiple myeloma-free survival was not significantly improved.

Read post

5. Metastasis-directed therapy linked to better control in metastatic nasopharyngeal cancer

Among 54 patients receiving definitive locoregional RT, two-year recurrence-free survival was 81.9% with metastasis-directed therapy versus 28.2% without. Major differences in metastatic burden and treatment selection limit causal interpretation.

Read post

That's the week. See you next Sunday.

Browse more research Suggest a correction